AZD 1744Alternative Names: AZD1744
Latest Information Update: 03 Nov 2008
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action CCR3 receptor antagonists; Histamine H1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 19 Feb 2007 Phase-I clinical trials in Asthma in United Kingdom (unspecified route)